ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

aTyr Pharma, Inc. (the “Company”) issued a press release on August 10, 2017 announcing that the Company will report its financial results for the second quarter 2017 after the U.S. financial markets close on Monday, August 14, 2017.

The information under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

99.1

Press Release of aTyr Pharma, Inc. dated August 10, 2017


aTYR PHARMA INC Exhibit
EX-99.1 2 life-ex991_6.htm EX-99.1 life-ex991_6.htm Exhibit 99.1   IMMEDIATE RELEASE   Contact:   Mark Johnson   Sr. Director,…
To view the full exhibit click here

About ATYR PHARMA, INC. (NASDAQ:LIFE)

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

An ad to help with our costs